Deletions in the dystrophin gene give rise to both Duchenne and Becker muscular dystrophies. Good correlation is generally found between the severity of the phenotype and the effect of the deletion on the reading frame: deletions that disrupt the reading frame result in a severe phenotype, while in frame deletions are associated with a milder disease course. Rare exceptions to this rule, mainly owing to frameshift mutations in the 5' region of the gene (in particular deletions involving exons 3 to 7) which are associated with a milder than expected phenotype, have been reported previously. In order to characterise better the relationship between genotype and phenotype as a result ofmutations arising in the 5' region of the gene, we have studied a large cohort of patients with smali in frame and out of frame deletions in the first 13 exons of the dystrophin gene. Fifty-five patients with a deletion in this area were identified; approximately one third of them had a phenotype different from that theoretically expected. Patients were divided into two groups: (1) patients with a severe clinical phenotype despite the presence of a small, in frame deletion and (2) patients with a mild phenotype and an out of frame deletion. Noticeable examples observed in the first group were Duchenne boys with a deletion ofexon 5, ofexon 3, and ofexons 3-13. In the second group we observed several patients with an intermediate or Becker phenotype and out of frame deletions involving not only the usual exons 3-7 but also 5-7 and 3-6. These data indicate that a high proportion of patients with a deletion in the 5' end of the gene have a phenotype that is not predictable on the basis of the effect of the deletion on the reading frame. The N-terminus of dystrophin has at least one actin binding domain that might be affected by the small, in frame deletions in this area. The effect of the in frame deletions of exon 3, 5, and 3-13 on this domain might account for the severe phenotype observed in these patients. Other mechanisms, such as unexpected effect of the deletion on splicing behaviour, might, however, also be implicated in determinining the phenotype outcome. (JMed Genet 1994;31:843-847) Duchenne and Becker muscular dystrophies (DMD and BMD) both arise from mutations in the dystrophin gene.'2 In the majority of patients affected by DMD and BMD, a deletion affecting one or more exons of the dystrophin gene is found after either Southern blotting or polymerase chain reaction (PCR) study of genomic DNA.`-5 In general the effect of the deletion on the reading frame was found to be in good agreement with the severity of the observed phenotype: deletions causing a frameshift were generally found to be associated with a severe DMD phenotype (irrespective of the size of the deletion), while deletions not affecting the reading frame were found to be associated with the milder BMD phenotype.6
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Regarding the multiple exon deletions, we have identifed one patient with an in frame deletion involving exons 3-13 and a Duchenne phenotype. The muscle of this boy, who became wheelchair bound at the age of 9, could also be visualised with antibodies raised against a portion of the protein distal to the deletion, confirming an in frame deletion. of them and showed a marked reduction in dystrophin abundance in all. There was apparently no correlation between the differences in size and amount of dystrophin (as judged by Western blot) and the severity of the phenotype (that is, both BMD and intermediate patipnts produced similar amounts of the protein). Immunocytochemical analysis of the muscle, performed in four of these patients, showed low dystrophin levels produced in all fibres.
PATIENTS WITH OUT OF FRAME DELETIONS BUT
In addition to this relatively large group of patients, we identified three persons with frameshift deletions internal to the relatively common 3-7 deletion: two of them had a 3-6 deletion (patients HH 8 and HH 9), while one was lacking exons 5-7 (patient HH 7). Of these patients, one had a typical BMD phenotype, being still ambulant at the age of 21, and a clear, although faint band on the Western blot corresponding to a lower molecular weight dystrophin. The other showed a DMD disease course, since he lost ambulation by the age of 11 years, and showed complete absence of dystrophin on immunocytochemistry.
The boy with the 5-7 deletion had an intermediate phenotype (lost ambulation at 14-5 years) and his muscle biopsy showed a complete lack of dystrophin.
Discussion
The majority of patients with DMD and BMD have deletions ofone or more dystrophin exons. Although there is good agreement between the HH =Hammersmith Hospital. The asterisk indicates a patient with a missense point mutation.
The symbol + or -in the frame column indicates the effect of the deletion on the reading frame. The exons in bold indicate cases described in the present article.
effect of the deletion on the reading frame and the observed phenotype, several exceptions have been previously reported. These rare cases are not only important because they highlight the pitfalls in giving a prognosis based exclusively on the genetic study results, but also because the mechanism responsible for the discrepancy found in these patients might help to indicate the function of specific dystrophin domains. In particular, in frame deletions removing single or few exons, but associated with more severe than expected phenotypes, might indicate that a specific portion of dystrophin is crucial for its function.
In this study we found that approximately one third of patients with mutations in the 5' region of the gene do not conform to the frameshift rule. We have divided our patients into two major categories: those with a small in frame deletion and a severe phenotype and those with out of frame deletions associated with relatively mild phenotypes.
In the first group of patients we have found deletions removing exons 3, 5, and 3-13. Only one patient had a deletion removing exon 3 alone; he had an intermediate phenotype. Mutations involving exon 3, which encodes for 31 amino acids, have only been reported in five other patients (table 2) . Their phenotype ranged from DMD to BMD.791225 The biochemical studies performed in these cases, as in our own, indicate the presence of dystrophin detected with antibodies directed towards regions 3' of the deletion, further indicating that the frame was maintained. Four of these patients had a deletion of exon 37912 and one had a missense mutation.25
Regarding the four patients with a deletion removing exon 5, they also had a relatively severe phenotype despite having a small, in frame deletion (exon 5 contains 31 amino acids). This deletion, as far as we are aware, has not been reported by other groups. Three of the patients with exon 5 deletions were classified as intermediate, while one had a DMD phenotype; dystrophin analysis performed in one of these patients confirmed the production of significant amounts of dystrophin in the region distal to the deletion.
One patient had an in frame deletion removing exons 3-13 and showed a typical DMD disease course. The phenotype of this patient was more severe than the one observed in patients with deletion of exon 3 or 5; another patient with the same deletion also showed a similar severe phenotype. '4 We have reviewed published cases with in frame deletions in this 5' region: the results are summarised in table 2. Analysis shows that in frame deletions in this region can result in great phenotypic variability, and not always in BMD, confirming what is reported in this study. In particular, deletions of exons 2-7, 3, 3-9, 5-13, 6-13, and [10] [11] [12] [13] have been frequently associated with disease courses more severe than expected (table 2) .
Regarding patients with single exon deletion, from the data regarding our own cases and those reported by others, one is tempted to conclude that both exon With regard to patients with out of frame deletions and milder than expected phenotypes, we found nine patients with deletions of exons 3-7. As already extensively described, we also found that the phenotype in this group of patients is rather variable, ranging from intermediate to BMD patients. We found no DMD in this category of patients, although there have been rare reports of such an association (table 2) .
Deletions internal to the typical exon 3-7 region have rarely been reported.71626 Although the conclusion of these studies was that the phenotype resulting from this type of internal deletion were not responsible for unusual phenotypes,'626 we have found that both deletions removing exons 5-7 and 3-6 (all out of frame) were associated with a wide spectrum of disease severity, ranging from a very mild BMD phenotype (one patient with a 3-6 deletion) to an intermediate or DMD phenotype (one patient with exon 5-7 and another with exon 3-6 deletion). The reason for this is not known, but some of the mechanisms that have been proposed to account for the relatively mild phenotype of patients with [3] [4] [5] [6] [7] deletions might also hold true in this category of patients. In this respect, it should be noticed that in one study performed in patients with a deletion of exon 3-7, minor alternative splicing phenomena in this 5' region of the cDNA were found (in particular splicing of exons 2-10, and of exons 1-8, which restore the reading frame but also minimal splicing out of exons 1-10, still being out of frame8). Other studies, however, have not confirmed these results.71 16 Why patients with out of frame deletions removing exons 3-7, 3-6, and 5-7 might have a phenotype milder than patients with single exon in frame deletions in this area has already been discussed,25 but is still unclear.
On the basis of our data, we can conclude that deletions in the 5' region of the dystrophin gene are frequently associated with unpredictable phenotypes; this information should be considered when counselling cases with such mutations. The data regarding severe patients with in frame deletions of single exons in this region might also suggest an important function of these sequences for protein stability or function.
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